National Institute for Health and Clinical Excellence (NICE)
Pregnant women to be offered first test to help diagnose pre-eclampsia
Midwives caring for pregnant women can use one of four blood tests to help diagnose suspected preterm pre-eclampsia, NICE has said in new draft diagnostic guidance.
The independent NICE diagnostic advisory committee has recommended four tests that can be used between 20 to 36 weeks and 6 days of pregnancy to help make decisions about caring for women presenting with suspected preterm pre-eclampsia.
Pre‑eclampsia is a potentially serious complication of pregnancy, thought to be related to problems with the development of the placenta.
Early signs of pre‑eclampsia include high blood pressure and having protein in the urine. Pre-eclampsia affects up to 6% of pregnancies, with severe pre-eclampsia developing in around 1-2% of UK pregnancies.
The recommended tests measure levels of placental growth factor (PLGF) in the blood. PLGF is a protein that helps the development of new blood vessels in the placenta. In pre-eclampsia levels of PLGF can be abnormally low and could be an indicator that the placenta is not developing properly.
Tests were previously only recommended by NICE for use to help rule out pre-eclampsia. Being able to help positively diagnose pre-eclampsia will lead to better care for the mother and her unborn baby. This can involve referral to a specialist and hospital admission to monitor the mother and unborn baby. Pre-eclampsia is only cured by delivery of the baby. Evidence presented to the committee showed that use of the tests did not lead to unnecessary early delivery.
If not monitored and treated, the condition can lead to serious complications for both mother and baby.
Recommendations on pre-eclampsia in NICE’s antenatal care guideline include measuring blood pressure and checking the urine for protein at each antenatal visit to check for pre-eclampsia. The guideline also recommends determining risk factors for pre-eclampsia at the booking appointment (by 10 weeks of pregnancy).
Jeanette Kusel, acting director for MedTech and digital at NICE, recently said:
“These tests represent a step change in the management and treatment of pre‑eclampsia.
“New evidence presented to the committee shows that these tests can help successfully diagnose pre‑eclampsia, alongside clinical information for decision-making, rather than just rule it out.
“This is extremely valuable to doctors and expectant mothers as now they can have increased confidence in their treatment plans and preparing for a safe birth.”
Dr Mark Kroese, chair of the NICE diagnostics advisory committee, recently said:
“The committee called for further research when it looked at this topic in 2016. Following some excellent research, we can now issue draft guidance for four test which the NHS can use to help diagnose pre‑eclampsia.”
A consultation on the draft recommendation is now open. Comments must be submitted via nice.org.uk before Tuesday 19 April 2022.
Original article link: https://www.nice.org.uk/news/article/pregnant-women-to-be-offered-first-test-to-help-diagnose-pre-eclampsia-nice-recommends-in-draft-guidance
Latest News from
National Institute for Health and Clinical Excellence (NICE)
Hundreds of people are set to receive the first immunotherapy drug for advanced cervical cancer through the Cancer Drugs Fund30/03/2023 11:05:00
Hundreds of people with cervical cancer are set to receive the first immunotherapy drug for an advanced form of the disease as NICE yesterday (Wednesday 29 March 2023) published the final draft guidance recommending its use in the Cancer Drugs Fund (CDF).
NICE identifies improvements for people with acute kidney injury in updated quality standard23/03/2023 15:30:00
An updated quality standard published today (23 March 2023) by NICE outlines improvements in care for people who have or are at risk of acute kidney injury
NICE recommends life-changing gene therapy for children with ultra-rare genetic disorder in final draft guidance23/03/2023 13:15:00
The first and currently only gene therapy for children with an ultra-rare genetic disorder has been recommended by NICE in final draft guidance published today (23 March 2023).
Four innovative tests for diagnosing UTIs could help in the fight against antimicrobial resistance21/03/2023 14:15:00
Innovative tests with the potential to help people with a urinary tract infection (UTI) receive the correct course of antibiotics more quickly could soon be considered for use in the NHS.
NICE recommended weight-loss drug to be made available in specialist NHS services08/03/2023 14:20:00
Thousands of people will soon be able to be prescribed a drug to help them lose weight as part of their treatment in an NHS specialist weight management service.
Eight digitally enabled therapies to treat depression and anxiety in adults conditionally recommended by NICE01/03/2023 13:20:00
Eight digital enabled therapies to treat depression and anxiety disorders in adults have been conditionally recommended by NICE in draft guidance issued today (Wednesday 1 March 2023)
NICE recommends 3 treatments for COVID-19 in final draft guidance21/02/2023 13:05:00
Everyone with COVID-19 at highest risk of developing severe disease will have access to clinically and cost-effective treatments, under final draft guidance published by NICE today.
NICE says evidence that COVID-19 treatment Evusheld is effective in protecting vulnerable adults against current variants is lacking as it announces new rapid update process for COVID-19 medicines16/02/2023 11:25:00
NICE has today (16 February 2023) issued draft guidance for public consultation which does not recommend Evusheld for preventing COVID-19 in adults who are unlikely to have an adequate immune response to COVID-19 vaccination, or who can’t be vaccinated
New NICE quality standard identifies improvements in UTI diagnosis for women15/02/2023 15:10:00
Health professionals should diagnose women under 65 with a urinary tract infection (UTI) if they have two or more key urinary symptoms according to a new quality standard published by NICE today (15 February 2023).